Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry+publication

Tuebingen intratympanic dexamethasone catheter SSNHL study

Also known as: Dexamethasone-dihydrogenphosphate 4 mg/mL, Inner ear topical dexamethasone, LOCAL DEX-ISSNHL, NCT00335920

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 3

Status

Completed

Target Gene

—

Route / Mode

Continuous intratympanic catheter infusion

Confidence

86%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Germany

Population

adult, sudden, sensorineural, unilateral

Trial IDs

Mechanism

Completed randomized placebo-controlled Phase 3 study of continuous two-week intratympanic dexamethasone delivery through a temporarily implanted round-window catheter after insufficient recovery from initial systemic therapy.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Corrected from a formulation-level drug row to the completed University Hospital Tuebingen intratympanic dexamethasone catheter study for idiopathic sudden sensorineural hearing loss. This is a historical institution-led study, not a commercial dexamethasone product.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT00335920

Open

publication

Supports: mechanism, status, notes, keyEvents

IDs: PMID:19172627

Open

Key Events

2003-10-01